Use of cross-protection to identify novel vaccine candidates for infectious agents

Abstract

This invention discloses methods for identifying Francisella tularensis vaccine candidates. It enables identification of novel vaccine candidates and quality assurance for vaccine batches, assessment of protection in vaccinates and identification of the infecting agent in vaccinates. Mice were first vaccinated with Brucella abortus O-polysaccharide (OPS) vaccine. These animals were then given 10 LD₅₀s of F. tularensis live vaccine strain (LVS). Sixty percent (60%) of the vaccinated mice survived the multiple lethal doses. Sera were collected from these surviving mice and the antibodies were used to probe supernatant and cell lysates of live F. tularensis LVS cultures. Several F. tularensis components were identified only by the noted “survivor” antisera. Of these identified proteins, enzyme digestions and chemical oxidation suggest post-translational modifications of some proteins e.g. a 52 kDa glycoprotein, a 45 kDa lipoprotein and a 19 kDa nucleoprotein. The 52 kDa component caused nitrous oxide induction in tissue cultures at low concentrations, cell death at high concentrations. Vaccination with this gave partial protection while addition of other components acted synergistically to give enhanced protection from 250 LD₅₀s of F. tularensis LVS.

Description

CROSS REFERENCE TO RELATED APPLICATION[0001]This application claims the benefit of Provisional Application No. 60 / 442,072, filed Jan. 24, 2003, the entire content of which is hereby incorporated by reference in this application.FIELD OF THE INVENTION[0002]The general field of the invention is the development of sub-cellular vaccines that induce immunity to infectious agents. More particularly, the invention relates to the identification of novel vaccine candidates (with logical extensions to other infectious agents such as other bacteria, fungi, yeast, viruses or parasites), quality assurance for vaccine batches, assessment of protection in vaccinated animals and the identification of the infecting agent in vaccinates.BACKGROUND OF THE INVENTIONList of Prior Art Literature[0003]Stewart, S. J. 1991. Francisella. In: Balows, A., W. J. Hausler, Jr., K. L. Herrmann, H. D. Isenberg, and H. J. Shadomy (ed.). Manual of Clinical Microbiology. Am. Society for Microbiology, pp. 454-456.[0004]...

AI Technical Summary

Benefits of technology

[0021]Specifically, mice were given a vaccine against one bacterium (O-polysaccharide, or OPS, vaccine which is protective against Brucella abortus) but then infected with multiple lethal doses (10 LD50) of another bacterium, Francisella tularensis. Due to cross-protection, most of the mice vaccinated against brucellosis survived tularemia. It was found that these surviving vaccinated mice had in their sera antibodies that recognized the

Problems solved by technology

A F. tularensis live vaccine strain (LVS) is available, but it has an IND (Investigational New Drug) status, its efficacy against exposures by different routes of infection is questionable (Evans and Friedlander, 1997) and under certain conditions it appears to revert to its virulent parental form (Cherwonogrodzky et al., 1994).

For the first part, vaccination often gives limited results (e.g. although the LVS protects against tularemia, its efficacy for protecting against infection by different routes is questionable) with antibody titers either being low or rapidly diminishing with time.

An infectio

Images